Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) Equity Average (2016 - 2025)

Utah Medical Products has reported Equity Average over the past 15 years, most recently at $118.8 million for Q4 2025.

  • Quarterly results put Equity Average at $118.8 million for Q4 2025, down 1.7% from a year ago — trailing twelve months through Dec 2025 was $118.8 million (down 1.7% YoY), and the annual figure for FY2025 was $118.3 million, down 3.68%.
  • Equity Average for Q4 2025 was $118.8 million at Utah Medical Products, up from $117.9 million in the prior quarter.
  • Over the last five years, Equity Average for UTMD hit a ceiling of $128.0 million in Q1 2024 and a floor of $103.9 million in Q1 2021.
  • Median Equity Average over the past 5 years was $117.3 million (2025), compared with a mean of $115.9 million.
  • Biggest five-year swings in Equity Average: increased 13.82% in 2023 and later decreased 8.43% in 2025.
  • Utah Medical Products' Equity Average stood at $108.6 million in 2021, then increased by 2.45% to $111.2 million in 2022, then increased by 13.3% to $126.0 million in 2023, then fell by 4.12% to $120.8 million in 2024, then dropped by 1.7% to $118.8 million in 2025.
  • The last three reported values for Equity Average were $118.8 million (Q4 2025), $117.9 million (Q3 2025), and $117.3 million (Q2 2025) per Business Quant data.